Statement: Neutropenia affected the majority of patients in cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 26/69 (37.68%)   Anaemia 2/69 (2.90%)   Febrile neutropenia 3/69 (4.35%)   Neutropenia 4/69 (5.80%)   Cardiac arrest 1/69 (1.45%)   Cardiac failure congestive 1/69 (1.45%)   Cardiac tamponade 1/69 (1.45%)   Pericardial effusion 1/69 (1.45%)   Abdominal pain 1/69 (1.45%)   Ascites 2/69 (2.90%)   Colitis 1/69 (1.45%)   Gastritis 1/69 (1.45%)   Gastritis erosive 1/69 (1.45%) Adverse Events 2:   Total: 12/65 (18.46%)   Anaemia 0/65 (0.00%)   Febrile neutropenia 1/65 (1.54%)   Neutropenia 1/65 (1.54%)   Cardiac arrest 0/65 (0.00%)   Cardiac failure congestive 0/65 (0.00%)   Cardiac tamponade 0/65 (0.00%)   Pericardial effusion 0/65 (0.00%)   Abdominal pain 2/65 (3.08%)   Ascites 2/65 (3.08%)   Colitis 0/65 (0.00%)   Gastritis 0/65 (0.00%)   Gastritis erosive 0/65 (0.00%)